ORCA Therapeutics B.V. is a privately-funded biopharmaceutical company designing and developing new oncolytic immunotherapies for treatment of cancer using Oncolytic Replication Competent Agents (ORCA). At ORCA, we are passionate about using viruses to cure cancer patients.  Our proprietary technologies allow us to engineer powerful oncolytic adenoviruses that selectively kill cancer cells and induce an antitumor immune response. ORCA’s lead compound ORCA-010 is being developed for treatment naive patients with prostate cancer.

ORCA’s technology and IP portfolio originates from the groundbreaking research performed at the Department of Medical Oncology at the VU University Medical Center (VUmc) in Amsterdam, the Netherlands. ORCA is expanding its product portfolio through alliances with academic centres of excellence and industry partners. ORCA is based in the Netherlands: its corporate office is located in Nijmegen and R&D operations are in Amsterdam.